article thumbnail

‘Care Anywhere’ is the new normal, according to new industry report

Healthcare It News

Before joining BCGDV, they practised as medical doctors or worked in industries such as health insurance, medtech or pharma”, the company spokesperson informed Healthcare IT News. In contrast, however, according to the authors, women take a predominant role in health decisions and have about one-third higher health expenditures.

COVID-19 219
article thumbnail

‘Care Anywhere’ is the new normal, according to industry report

Healthcare It News

Before joining BCGDV, they practised as medical doctors or worked in industries such as health insurance, medtech or pharma”, the company spokesperson informed Healthcare IT News. In contrast, however, according to the authors, women take a predominant role in health decisions and have about one-third higher health expenditures.

COVID-19 211
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

5 Key Trends in Women’s Health Technology for 2023 to Watch

HIT Consultant

Education and conversation around women’s healthcare are evolving, however, women’s health technology is still, by far, an emerging industry. For example, only 3% of the 2,728 US digital health deals since 2011 have focused on women’s health.

FDA 98
article thumbnail

President Biden Signs End-of-Year Legislation Including Telehealth, Medicare & Medicaid, Mental Health, Pandemic Preparedness, and Other Health Care Provisions

C&M Health Law

The Act’s health care offset title includes Section 4163, which extends the 2% Budget Control Act of 2011 Medicare sequester for six months into FY 2032 and lowers the payment reduction percentages in FYs 2030 and 2031. The Act also provides investments in Medicaid and the Children’s Health Insurance Program (CHIP).

Medicaid 104
article thumbnail

FDA and Off-Label Communication – Getting Closer to Truth

Drug & Device Law

In addition to its recent revamp of its “§510(k)” substantial equivalence clearance process for medical devices, (see our post here ), the FDA has also been active with respect to off-label communications – another regulatory area of continuing interest to this Blog. IMS Health Inc. , 552 (2011); Thompson v. FDA , 119 F.

FDA 64